Companies › Beijing Suncadia Pharmaceuticals
4 active drug programs in 6 registered trials: 3 Phase 2, 2 Phase 3, 1 Phase 1; Metabolic and endocrine, Neurology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| SHR-1918 APOB mRNA antisense oligonucleotide | APOB | Phase 3 | Hypertriglyceridemia; Hyperlipidemia; Hypercholesterolemia | Mar 2027 |
| HRS-4029 | – | Phase 2 | Acute Ischemic Stroke | Apr 2027 |
| HRS8179 injection | – | Phase 2 | Severe Cerebral Edema Following Large Hemispheric Infarction | Jun 2027 |
| SHR-2906 Injection | – | Phase 1 | Obesity | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07280936 | SHR-2906 Injection | Phase 1 | Obesity | Metabolic and endocrine | Dec 2026 |
| NCT07349615 | SHR-1918 | Phase 3 | Hypertriglyceridemia | Metabolic and endocrine | Mar 2027 |
| NCT07739160 | HRS-4029 | Phase 2 | Acute Ischemic Stroke | Neurology | Apr 2027 |
| NCT06732648 | HRS8179 injection | Phase 2 | Severe Cerebral Edema Following Large Hemispheric Infarction | Neurology | Jun 2027 |
| NCT07230730 | SHR-1918 | Phase 3 | Hyperlipidemia | Metabolic and endocrine | Oct 2027 |
| NCT07404553 | SHR-1918 | Phase 2 | Hypercholesterolemia | Metabolic and endocrine | Jul 2028 |
Alnylam Pharmaceuticals Vir Biotechnology Arrowhead Pharmaceuticals
Corxel Pharmaceuticals Shenzhen Wingor Biotechnology NeuroBiogen MediciNova PRG Science & Technology
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.